Scientists have added a sense of touch to a brain interface. This is key to making simple tasks possible for those who are paralyzed by stroke or spinal injuries.
Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband isn't sure if it made a difference.